Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
68.63
-3.27 (-4.55%)
At close: Apr 28, 2026, 4:00 PM EDT
68.42
-0.21 (-0.31%)
After-hours: Apr 28, 2026, 7:49 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 85.08, with a low estimate of 53 and a high estimate of 106. The average target predicts an increase of 23.97% from the current stock price of 68.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Spyre Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 7 |
| Buy | 2 | 2 | 2 | 3 | 3 | 5 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Maintains $64 → $95 | Strong Buy | Maintains | $64 → $95 | +38.42% | Apr 17, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $90 | Buy | Maintains | $50 → $90 | +31.14% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $65 → $80 | Buy | Maintains | $65 → $80 | +16.57% | Apr 14, 2026 |
| Baird | Baird | Buy Maintains $65 → $90 | Buy | Maintains | $65 → $90 | +31.14% | Apr 14, 2026 |
| Raymond James | Raymond James | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +16.57% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.98
from -1.98
EPS Next Year
-3.19
from -2.98
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.11 | -1.48 | ||||||
| Avg | -2.98 | -3.19 | ||||||
| Low | -3.91 | -4.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.